Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-09-15

FDA Approved: STRIBILD — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

FDA approved the supplemental application for STRIBILD (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) from Gilead Sciences, Inc. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Stribild (elvitegravir; cobicistat; emtricitabine; tenofovir disoproxil fumarate)

Snippet

SUPPL AP for STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE)